A Comprehensive Review of Stimulant-Induced Cardiotoxicity and Pharmacological Countermeasures

Chapter 1: The Pathophysiology of Stimulant-Induced Cardiovascular Toxicity

1.1 The Sympathomimetic Cascade: Catecholamine Toxicity, Hemodynamics, and Vasospasm

The primary driver of cardiovascular toxicity across all classes of central nervous system (CNS) stimulants, including amphetamine-type stimulants (ATS) (1) and methylphenidate (2), is their fundamental sympathomimetic mechanism. These agents amplify catecholamine neurotransmission, principally norepinephrine (NE) and dopamine (DA), leading to a state of chronic sympathetic activation.(2, 3) This persistent overstimulation of adrenergic receptors throughout the cardiovascular system precipitates a cascade of deleterious hemodynamic effects.

The most immediate consequences are increases in heart rate (tachycardia) and blood pressure (hypertension).(4, 5) This is mediated by the activation of beta-1-adrenoceptors, which increases chronotropy and inotropy, and alpha-1-adrenoceptors, which mediates peripheral vasoconstriction and increases systemic vascular resistance.(1, 2) This dual burden forces the heart to beat faster and more forcefully against a greater resistance, significantly increasing myocardial oxygen demand. In vulnerable individuals or in acute overdose, this hemodynamic strain can manifest as coronary vasospasm (1), acute myocardial infarction (AMI) (6, 7), coronary artery rupture (8), and life-threatening tachyarrhythmias.(2, 9) While these acute events are well-documented, it is the prolonged, chronic exposure to this state of hemodynamic overdrive that initiates the more insidious, long-term pathological remodeling.(1, 3)

1.2 Cellular and Molecular Mechanisms: Oxidative Stress, Calcium Dysregulation, and Apoptosis

Beyond the macro-hemodynamic strain, a more direct and discrete cellular toxicity occurs. The pathophysiology of stimulant-induced cardiotoxicity is multifactorial, representing a "dual-hit" model where hemodynamic stress is compounded by direct cellular pathology. A systematic review identified a

constellation of likely mechanisms at the cardiomyocyte level.(10)

Chief among these is oxidative stress (OS).(1, 10) Preclinical studies in animal models demonstrate that both amphetamines and methamphetamines generate significant oxidative stress.(10, 11) This is not merely a downstream effect; the oxidation products of catecholamines themselves are directly cytotoxic.(12) This persistent OS, driven by sources such as mitochondrial reactive oxygen species (ROS) (3), creates a vicious cycle of mitochondrial dysfunction that is known to be causal in cardiac hypertrophy, fibrosis, and heart failure progression.(3, 13)

This oxidative environment disrupts intracellular ion homeostasis, particularly leading to defects in intracellular calcium (Ca^{2+}) regulation.(10) The concept of Ca^{2+} overload as a final common pathway for myocardial injury, first established in isoproterenol (a synthetic catecholamine) models, is directly applicable.(12) This combination of rampant oxidative stress and calcium dysregulation activates pro-apoptotic signaling pathways, leading to accelerated cardiomyocyte apoptosis (10), increased p53 activity (10), and focal cardiomyocyte necrosis.(10)

This "dual-hit" understanding—where the heart is simultaneously subjected to (1) relentless hemodynamic strain and (2) direct, pro-oxidant cellular toxicity—is a foundational concept. It dictates that any truly effective cardioprotective strategy *must* be bifurcated: it must not only manage the symptomatic tachycardia and hypertension but must also address the underlying cellular and mitochondrial oxidative damage.

1.3 Pathological Sequelae: Amphetamine-Associated Cardiomyopathy (ATSAC) and Pathological Remodeling

The long-term, cumulative result of these chronic hemodynamic and cellular insults is the development of structural heart disease, specifically Amphetamine-Type Stimulants Associated Cardiomyopathy (ATSAC).(10) This condition is emerging as a novel and distinct clinical entity. Often, patients present late in the disease course with severe, dilated cardiomyopathy.(10, 14) Specific phenotypes have also been observed, such as a prevalence of Takotsubo (stress-induced) cardiomyopathy, particularly its atypical basal variant, in female ATS users.(10)

Crucially, this risk is not confined to illicit or high-dose abusers. A 2024 study presented at the American College of Cardiology's Annual Scientific Session provided alarming evidence from therapeutic users. Young adults prescribed stimulants (both Adderall and Ritalin) demonstrated a significantly increased risk of developing cardiomyopathy compared to non-users.(15) The risk was found to be duration-dependent: patients were 17% more likely to develop cardiomyopathy at one year, and this relative risk rose to 57% by the eight-year mark.(15) While the researchers characterized the absolute risk as low, the statistically significant, duration-dependent relative risk confirms that long-term therapeutic use is a non-trivial risk factor for pathological cardiac remodeling.

A critical and hopeful finding, however, is the potential for recovery. Unlike some other etiologies of heart failure, ATSAC appears to possess "some degree of reversibility and recovery" following the

complete cessation of stimulant exposure.(10) This single finding provides the central rationale for adjunctive cardioprotective therapy. If the pathology is reversible upon removal of the offending agent, it implies the damage is not immediately permanent. This suggests that a pharmacological strategy designed to mimic "cessation" at the myocardial level—by blocking both the hemodynamic and cellular "hits"—could theoretically halt or even reverse pathological remodeling, all while the patient continues to receive the stimulant's necessary CNS benefits.

1.4 Comparative Toxicological Profiles: Amphetamine vs. Methylphenidate

While amphetamines (e.g., Adderall; a reuptake inhibitor and releasing agent) and methylphenidate (e.g., Ritalin; primarily a reuptake inhibitor) possess distinct primary mechanisms of action in the CNS, their cardiovascular risk profiles appear to be clinically indistinguishable.

The literature consistently groups them, finding shared mechanisms and outcomes.

- The 2024 ACC study, for instance, grouped "Adderall and Ritalin" together when identifying the long-term risk of cardiomyopathy.(15)
- A population-based study assessing emergency department visits for cardiac reasons found a *similar risk* for both methylphenidate and amphetamine users.(16)
- A systematic review and meta-analysis of cardiovascular effects in children and adolescents found small but statistically significant pre-post increases in systolic blood pressure (SBP) and diastolic blood pressure (DBP) for *both* drug classes.(5)
- The underlying mechanism is believed to be the same: the "cardiopressor dopaminergic/noradrenergic effects" that lead to increased heart rate and blood pressure.(4)

This implies that the specific pharmacological route to achieving sympathomimetic over-activation is less relevant than the *fact* of the over-activation itself. Therefore, the cardioprotective and monitoring strategies discussed in this report should be considered class-agnostic and equally applicable to patients on long-term therapy with either amphetamines or methylphenidate.

Chapter 2: Diagnostic and Cardiovascular Monitoring Protocols

2.1 Baseline Risk Stratification: Patient History, Family History, and Physical Examination

Prior to the initiation of any CNS stimulant therapy, a thorough cardiovascular assessment is mandatory. This evaluation serves as the primary risk stratification tool, and its foundation is a meticulous patient and family history.

The history must actively screen for symptoms suggestive of an underlying cardiac condition, including

any patient report of (17):

- Syncope (fainting) or pre-syncope (dizziness), especially if exertional.
- Shortness of breath or chest pain, particularly with exertion.
- Palpitations or a known history of heart murmur, high blood pressure, or arrhythmia.

A comprehensive family history is equally critical and must include specific inquiries regarding (17, 18):

- Sudden cardiac death (SCD) or unexplained sudden death in any first- or second-degree relative under the age of 35.
- Known family history of inheritable cardiac conditions, such as hypertrophic cardiomyopathy (HCM), long QT syndrome (LQTS) or other ion channelopathies, or arrhythmogenic right ventricular cardiomyopathy.(17)

A baseline physical examination, including vital signs (heart rate and blood pressure percentile-adjusted for age and height) and auscultation for murmurs or abnormal rhythms, is also required.(17) A positive finding on *any* component of this history or physical exam warrants an immediate "pause" on stimulant initiation and a referral to a cardiologist for further evaluation *before* the medication is prescribed.(17)

2.2 The Electrocardiogram (ECG) Guideline Conflict: An Analysis of AHA, AAP, and AACAP Stances

The role of a *routine baseline* electrocardiogram (ECG) for all patients being considered for stimulant therapy has been a subject of significant clinical controversy. In 2008, the American Heart Association (AHA) issued a scientific statement, classified as a Class IIa (Reasonable) recommendation with Level of Evidence C (Expert Opinion), suggesting it was "reasonable to obtain ECGs" for all children before starting stimulants.(17, 18) The rationale was that an ECG is a non-invasive tool that could identify "silent" but high-risk conditions, such as HCM, LQTS, and Wolff-Parkinson-White (WPW) syndrome, which could predispose a patient to SCD under sympathomimetic challenge.(17)

This recommendation was immediately and publicly contradicted by the American Academy of Pediatrics (AAP) (18) and the American Academy of Child and Adolescent Psychiatry (AACAP). Their counter-argument was threefold:

1. The incidence of SCD in children taking stimulants is exceptionally rare, occurring at rates no higher than, and possibly lower than, those in the general pediatric population.(18)
2. There was (and is) no evidence that routine ECG screening in an asymptomatic, history-negative population would effectively prevent these rare events.
3. Mandating universal ECG screening would create significant barriers to necessary psychiatric care, including increased costs, specialist delays, and a high rate of false positives leading to unnecessary anxiety and further testing.(18)

The clinical consensus has since resolved this conflict. A subsequent joint statement from the AAP and AHA, along with current guidelines, has clarified that a baseline ECG is *not* a mandatory requirement.(18) The standard of care has coalesced around a "history-first" approach. The thorough

history and physical exam (from 2.1) remain the primary screening tools. An ECG is no longer considered a *routine screening* test but a *medically-indicated diagnostic* test, to be ordered *only* for those patients who "screen positive" on their history, family history, or physical examination.(18)

2.3 Monitoring Iatrogenic Hypertension: The Role of Ambulatory Blood Pressure Monitoring (ABPM)

Given that hypertension is a primary and predictable hemodynamic effect of stimulants, vigilant blood pressure monitoring is essential. The standard protocol involves checking BP and heart rate at baseline, following every dose titration, and periodically during maintenance therapy.(17)

However, in-office BP readings are often insufficient for managing iatrogenic hypertension. These "snapshot" readings are confounded by "white-coat" hypertension, patient anxiety, and the timing of the measurement relative to the medication's pharmacokinetics. If a patient shows persistent BP elevation (e.g., >95th percentile) in the office, a referral to a specialist for 24-hour Ambulatory Blood Pressure Monitoring (ABPM) is the recommended next step.

A novel and highly effective ABPM protocol has been developed specifically for this clinical question.(19) This protocol involves the patient undergoing *two* 24-hour monitoring periods: one day *while taking* their stimulant medication and a second day *while abstaining* from it. This "on/off" methodology provides a perfect internal control and is the *only* way to definitively phenotype the patient's hypertension. It allows the clinician to distinguish between:

1. **Pre-existing or Essential Hypertension:** The patient is hypertensive on *both* days.
2. **Iatrogenic Stimulant-Induced Hypertension:** The patient demonstrates normal BP on their "off" day and clear hypertension *only* on the "on" day.(19)

This distinction is clinically paramount, as it dictates whether the appropriate management is to initiate antihypertensive therapy (to be co-administered with the stimulant) or to reduce or discontinue the stimulant itself. This monitoring should also be intelligently timed to the stimulant's pharmacokinetics to capture peak effects, for example, 4 hours post-dose for immediate-release (IR) formulations or 8-12 hours post-dose for extended-release (ER) formulations.(20)

2.4 Advanced Surveillance: Echocardiography and Stress Testing for Long-Term Structural Assessment

Advanced imaging, such as an echocardiogram, is *not* a baseline *screening* tool for the general asymptomatic population.(18) It is a *diagnostic* test employed by cardiologists as part of a workup *after* a patient has been flagged as high-risk by their history, physical exam, or an abnormal ECG.(17, 18)

However, the 2024 data demonstrating a significant, duration-dependent risk of cardiomyopathy, with risk rising sharply after eight years of *therapeutic* use, presents a compelling rationale for a new, longitudinal surveillance protocol.(15) Current guidelines, which were largely written before this long-term risk was quantified, focus only on *baseline* screening.

A logical and preventative extension of these new data would be to consider periodic echocardiographic surveillance for patients on long-term, high-dose therapy. While not yet the standard of care, a protocol involving a baseline echocardiogram at initiation, followed by repeat imaging every 5 to 10 years, could serve as a vital tool for detecting the subclinical, "silent" structural changes of ATSAC (10) before they progress to severe, symptomatic heart failure.

Chapter 3: Management of Stimulant-Induced Tachycardia

3.1 Ivabradine: Selective Sinoatrial Node Modulation

Ivabradine represents a highly specialized, precision-pharmacology tool for managing the isolated sinus tachycardia frequently caused by stimulants.

3.1.1 Pharmacodynamics (I(f) "Funny Current" Inhibition) and Pharmacokinetics

Ivabradine is described as a "pure" heart-rate-lowering agent.(21) Its mechanism of action is unique and highly specific: it is a use-dependent, selective inhibitor of the I_f "funny current" (hyperpolarization-activated cyclic nucleotide-gated, or HCN, channel).(22, 23) The HCN4 isoform is predominantly responsible for the spontaneous diastolic depolarization in the sinoatrial (SA) node, which functions as the heart's primary pacemaker.(22) By inhibiting this current, Ivabradine flattens the slope of diastolic depolarization, thereby slowing SA node firing and, consequently, reducing heart rate.(21)

The critical distinction of this mechanism is its selectivity. Unlike beta-blockers or non-dihydropyridine calcium channel blockers, Ivabradine has *no effect on myocardial contractility (inotropy)*, atrioventricular conduction, ventricular repolarization, or vascular tone (blood pressure).(21, 24) This allows it to isolate and treat tachycardia without causing the common side effects of fatigue, hypotension, or blunted exercise response associated with beta-blockade. Pharmacokinetically, the heart rate reduction is non-linear, reaching a plateau at higher oral doses (e.g., >24 mg).(25, 26)

3.1.2 Clinical Application and Dosing for Inappropriate Sinus Tachycardia (IST) and POTS

While Ivabradine is approved (on-label) for specific subsets of patients with Heart Failure with Reduced Ejection Fraction (HFrEF) (24, 27), its most frequent off-label application in electrophysiology is for the treatment of Inappropriate Sinus Tachycardia (IST) and Postural Orthostatic Tachycardia Syndrome (POTS).(24, 28, 29, 30)

These conditions, characterized by a persistently elevated sinus heart rate unexplained by physiologic demand, serve as a direct clinical proxy for the sympathomimetic-driven sinus tachycardia experienced by stimulant users. In this population, Ivabradine has proven highly effective and well-tolerated, with retrospective studies and meta-analyses demonstrating significant symptomatic improvement in 60-78% of patients, many of whom were intolerant to beta-blockers.(24, 31)

A hypothetical but clinically-grounded treatment plan for a stimulant user with persistent, symptomatic

sinus tachycardia (e.g., resting HR > 90-100 bpm) refractory to dose reduction would mirror these IST protocols. Dosing is typically initiated at 2.5 mg or 5 mg twice daily (BID), and titrated based on heart rate response, with target doses often falling between 5 mg and 7.5 mg BID.(32)

Furthermore, preclinical animal models suggest a deeper, "heart-rate-independent" cardioprotective effect. In models of myocardial ischemia/reperfusion, Ivabradine was found to reduce infarct size and improve cardiomyocyte viability, a benefit that persisted *even when heart rate was held constant* via atrial pacing.(33) This profound finding was attributed to *reduced mitochondrial ROS formation*.(33) This suggests Ivabradine may not just be masking a symptom (tachycardia) but may be *directly* treating the underlying cellular oxidative stress pathology identified in Chapter 1, making it an exceptionally compelling candidate.

3.2 Beta-Adrenergic Antagonists (Beta-Blockers)

3.2.1 Deconstructing the "Unopposed Alpha-Stimulation" Dogma: Acute Toxicity vs. Chronic Cardiomyopathy

A pervasive clinical dogma often prevents the use of beta-blockers (BBs) in stimulant users.(34, 35) This is the "perceived risk of 'unopposed alpha-receptor stimulation'").(35) The theory posits that blocking vasodilating beta-2-receptors will allow the stimulant's potent alpha-1-mediated vasoconstriction to dominate, paradoxically worsening hypertension and coronary vasospasm.(9, 36)

However, a critical review of the literature reveals this fear is largely based on "experimental studies and some case reports" (9) and represents a *contextual error*.

- **Acute Toxicity:** AHA guidelines *do* advise against BBs in the setting of *acute stimulant intoxication* (e.g., overdose in the emergency department) *unless* a primary coronary vasodilator (like nitroglycerin or phentolamine) is administered concurrently.(35)
- **Chronic Therapy:** This contraindication *does not* apply to the chronic, therapeutic use of stimulants. For a patient who develops stimulant-induced cardiomyopathy or hypertension, BBs are a safe, effective, and necessary component of standard-of-care, guideline-directed medical therapy.(34, 35, 37)

Evidence from high-risk populations supports this. A retrospective study of 503 heart failure patients with *active, comorbid cocaine-use disorder* found that those treated with the beta-blocker carvedilol had *lower rates of cardiovascular death and 30-day hospital readmission* than those not on a BB.(34) This demonstrates that in the chronic setting, the well-established benefits of beta-blockade in heart failure (38, 39) far outweigh the theoretical, and likely rare, risks.(9) Withholding this life-saving therapy from a stimulant user who develops cardiomyopathy is not supported by evidence and is likely to cause harm.(34, 35)

3.2.2 Preferred Agents for Cardioprotection

Not all beta-blockers are equivalent. Evidence from meta-analyses has demonstrated that older, second-generation non-vasodilating agents (like atenolol and propranolol) are less effective and may be associated with negative metabolic effects.(40) For cardioprotection, the "third-generation" vasodilating beta-blockers are strongly preferred, specifically Carvedilol and Nebivolol.

3.2.3 Profile: Carvedilol (B1/B2/A1 Blockade, Antioxidant Properties, PK/PD)

Carvedilol is a "multiple-action" agent uniquely suited to counteract stimulant-induced cardiotoxicity.(41)

- **Pharmacodynamics (PD):** Carvedilol is a non-selective beta-blocker (antagonizing both beta-1 and beta-2 receptors) that *also* possesses potent alpha-1-adrenergic blocking activity.(41, 42, 43) This dual-blockade *perfectly* maps to the "dual-hit" hemodynamic pathology:
  1. **beta-blockade:** Reduces heart rate and contractility, lowering myocardial work.(41)
  2. **alpha-1-blockade:** Directly antagonizes the stimulant's alpha-1-mediated vasoconstriction, causing vasodilation and reducing afterload.(41) This afterload reduction offsets the negative inotropic effect of beta-blockade, thereby maintaining cardiac output.(40, 41)
  3. **Antioxidant Properties:** A crucial non-receptor effect. Carvedilol and its metabolites are potent antioxidants.(41, 44) This property allows it to inhibit the "direct cytotoxic actions of reactive oxygen radicals" (41), directly targeting the *cellular* pathology of oxidative stress identified in Chapter 1. It may also inhibit inflammatory gene expression and LDL oxidation.(41)
- **Pharmacokinetics (PK):** Carvedilol is rapidly absorbed (Tmax 1-2 hours) (43, 45) but has a low absolute bioavailability (25-35%) due to extensive first-pass metabolism.(42, 46) It is highly lipophilic and protein-bound (98%).(45, 46) Metabolism is primarily hepatic, via CYP2D6 and CYP2C9.(46, 47, 48) This creates a potential for drug-drug interactions, as many amphetamines are also CYP2D6 substrates. The elimination half-life is 7-10 hours.(42, 46)

3.2.4 Profile: Nebivolol (B1-Selectivity, B3-Agonism, and NO-Mediated Vasodilation, PK/PD)

Nebivolol is another third-generation agent with a distinct, "endothelial-centric" mechanism.

- **Pharmacodynamics (PD):** Nebivolol is a racemic mixture. The d-enantiomer is a *highly selective* beta-1-antagonist.(49) The l-enantiomer is a *beta-3-receptor agonist*.(49) This unique beta-3-agonism stimulates endothelial nitric oxide synthase (eNOS) via the L-arginine/nitric oxide (NO) pathway, promoting the release of NO.(49, 50) This NO-mediated mechanism provides:
  1. **Vasodilation:** Leading to a reduction in peripheral vascular resistance.(49)
  2. **Antioxidant/Anti-inflammatory Effects:** This pathway directly attenuates oxidative stress. Preclinical studies show nebivolol significantly decreases malondialdehyde (MDA, a marker of oxidation) (50, 51) and inhibits inflammatory mediators like TNF-alpha and IL-1beta.(50)
- **Pharmacokinetics (PK):** Nebivolol reaches peak plasma concentration in 1.5-4 hours and is 98%

protein-bound.(49, 52) It is primarily metabolized by CYP2D6 (49, 52), again posing a risk for interactions with stimulants. Its elimination half-life is highly dependent on CYP2D6 metabolizer status, averaging 12 hours in extensive metabolizers but extending to 19 hours in poor metabolizers.(49)

Chapter 4: Management of Stimulant-Induced Hypertension

4.1 Renin-Angiotensin-Aldosterone System (RAAS) Modulators

4.1.1 Rationale: Stimulant-Induced RAAS Sensitization

The use of Renin-Angiotensin-Aldosterone System (RAAS) inhibitors, such as Angiotensin-Converting Enzyme (ACE) inhibitors and Angiotensin II Receptor Blockers (ARBs), is not merely a general antihypertensive strategy; it is a highly targeted, mechanistic intervention. Preclinical research in rats has revealed a profound insight: repeated amphetamine administration *centrally sensitizes the RAAS system*.(53)

This research demonstrated that a 7-day pretreatment with amphetamine not only induced and maintained a sensitized hypertensive response to a later challenge with Angiotensin II, but it also *upregulated mRNA expression for RAAS components* and neuroinflammation within the lamina terminalis.(53) The lamina terminalis is a critical forebrain region that controls sympathetic nervous system tone and blood pressure. This finding suggests that chronic stimulant use "reprograms" the brain to be hyper-responsive to RAAS signaling, creating a feed-forward loop of hypertension. This elevates RAAS modulators from general-purpose tools to *specific countermeasures* that block a pathway directly sensitized by the stimulant itself.

4.1.2 ACE Inhibitors (e.g., Lisinopril): Pharmacological Profile and Interactions

- **Pharmacodynamics (PD):** Lisinopril is a "first-line" antihypertensive.(54) As an ACE inhibitor, it blocks the enzyme that converts angiotensin I to the potent vasoconstrictor angiotensin II.(55, 56) This action results in vasodilation, decreased aldosterone secretion (leading to mild natriuresis), reduced sympathetic tone, and an overall decrease in cardiac workload.(55, 57) It is highly effective in treating hypertension and heart failure and provides vasculoprotective and cardioprotective benefits.(55, 58)
- **Pharmacokinetics (PK):** Lisinopril possesses a "clean" and highly advantageous PK profile for polypharmacy.
    1. It is *not a prodrug* (unlike enalapril).(59)
    2. It is *hydrophilic* and *not metabolized by the liver* (i.e., not a CYP450 substrate).(60)
    3. It is excreted entirely unchanged in the urine.(60)

Its bioavailability is approximately 25% (61), it has a slow time-to-peak concentration (Tmax) of 6-8 hours, and an effective half-life of 12.6 hours, permitting once-daily dosing.(60, 61) This PK profile is ideal for a stimulant user who may already be taking a stimulant (CYP2D6) and a third-generation beta-blocker (CYP2D6). Lisinopril's renal-only excretion completely bypasses this CYP450 "traffic jam," preventing unpredictable drug interactions.

- **Interactions:** The primary interaction is pharmacodynamic, not pharmacokinetic. Amphetamines increase blood pressure and may directly counteract the antihypertensive activity of ACE inhibitors, necessitating close BP monitoring.(62)

4.1.3 ARBs (e.g., Losartan): Pharmacological Profile and Active Metabolites

- **Pharmacodynamics (PD):** Losartan is an Angiotensin II Receptor Blocker (ARB).(63) Instead of blocking the production of angiotensin II, it selectively and competitively blocks its binding to the AT1 receptor, the receptor responsible for vasoconstriction, aldosterone release, and sympathetic activation.(64, 65) This provides similar cardioprotective and antihypertensive outcomes to ACE inhibitors, often with a lower incidence of the characteristic "ACE inhibitor cough".(64, 66)
- **Pharmacokinetics (PK):** Unlike lisinopril, losartan *is a prodrug*. Following oral administration, it undergoes significant first-pass metabolism by CYP2C9 and CYP3A4, with approximately 14% of the dose being converted to its active metabolite, E-3174.(64, 67) This metabolite is 10-40 times more potent than losartan and has a much longer elimination half-life (6-9 hours vs. 1.5-2 hours for losartan), meaning E-3174 is responsible for the majority of the drug's clinical effect.(64, 67)

4.2 Calcium Channel Blockers (CCBs)

4.2.1 Dihydropyridines (e.g., Amlodipine): Preclinical Data and CNS Penetration

- **Pharmacodynamics (PD):** Dihydropyridine calcium channel blockers (CCBs), such as amlodipine, are potent antihypertensives. They act by blocking L-type calcium channels in vascular smooth muscle, preventing calcium influx and causing peripheral vasodilation.(68)
- **Novel Rationale:** Recent, compelling preclinical studies have investigated amlodipine as a potential *novel, non-stimulant treatment for ADHD*.(68, 69) These studies, using both zebrafish and traditional rat models, found that amlodipine:
  1. Effectively *crosses the blood-brain barrier*.(68)
  2. *Reduces telencephalic activation* (brain activity).(68)
  3. *Significantly reduces hyperactivity* and impulsivity.(68, 69)
- This presents a potential *dual-action* therapeutic strategy. For a patient with stimulant-induced hypertension, the addition of amlodipine (on-label) could not only control their blood pressure but also provide *additive ADHD symptom control*. This synergistic effect could then allow the clinician to reduce the stimulant dose—the most effective harm-reduction strategy of all.(70)

4.2.2 Clinical Cautions and Drug Interactions

A critical distinction must be made within the CCB class. The dihydropyridine agents (e.g., amlodipine, felodipine) are appropriate, as they primarily act as peripheral vasodilators. However, the *non-dihydropyridine* CCBs (e.g., verapamil, diltiazem) *must be avoided*. These agents have significant negative chronotropic (heart rate) and inotropic (contractility) effects, and their co-administration with stimulants or other cardiovascular drugs can lead to adverse interactions and hemodynamic compromise.(71)

4.3 Alpha-2 Adrenergic Agonists (Guanfacine, Clonidine)

4.3.1 Dual-Purpose Adjunctive Therapy: PK/PD and Mechanism of Action

The central alpha-2-adrenergic agonists, clonidine and guanfacine, occupy a unique space in this discussion, as they are FDA-approved for treating *both* hypertension and ADHD.(72, 73)

- **Pharmacodynamics (PD):** Both drugs act as agonists at central alpha-2-receptors, which reduces sympathetic outflow from the brain, leading to decreased heart rate, reduced peripheral resistance, and lower blood pressure.(72, 74) For ADHD, this mechanism is thought to strengthen working memory and attention by agonizing alpha-2A-receptors in the prefrontal cortex.(75, 76)
- **Selectivity:** Clonidine is non-selective, stimulating alpha-2A, alpha-2B, and alpha-2C subtypes, as well as imidazoline receptors.(77) Guanfacine is *highly selective* for the alpha-2A-receptor, which is concentrated in the prefrontal cortex and may offer a more targeted ADHD effect with less sedation.(74, 75, 77)
- **Pharmacokinetics (PK - Guanfacine):** Guanfacine (extended-release, or ER) has a long elimination half-life of approximately 17 hours, permitting once-daily dosing.(74) It is primarily metabolized by CYP3A4, which can be affected by inhibitors or inducers, but it does *not* significantly affect the pharmacokinetics of co-administered methylphenidate or lisdexamfetamine.(78)

4.3.2 Attenuation of Stimulant-Induced Hemodynamic Effects

These agents serve as a premier, evidence-based harm reduction strategy. An international network meta-analysis of all ADHD medications confirmed that stimulants (MPH, AMP) and non-stimulants like atomoxetine *all* caused small but significant *increases* in blood pressure and heart rate.(79) In contrast, *only guanfacine* was associated with *decreased* hemodynamic values.(79, 80)

Clinical studies of combination therapy (Stimulant + Guanfacine ER) have confirmed this attenuating effect. The addition of guanfacine was found to *mitigate the heart rate increases* associated with stimulant monotherapy.(81) This allows for a synergistic treatment model where the two drug classes have *opposing* cardiovascular effects that hemodynamically "cancel each other out," while providing additive, or even synergistic, therapeutic benefit for ADHD symptoms.

Chapter 5: Systemic Substrates and Supplemental Adjuncts

This chapter addresses nutritional and supplemental adjuncts, framed not as general wellness but as targeted "substrate repletion." Chronic stimulant use places an exceptionally high metabolic demand on several key systems: (1) mitochondrial energy production, which is strained by oxidative stress; (2) endothelial function, which is strained by vasoconstriction and NO demand; and (3) ion homeostasis, which is strained by altered catecholamine-dependent channel flux. The following supplements aim to provide the raw materials to support these specific, strained pathways.

5.1 Mitochondrial Support: Coenzyme Q10

- **Mechanism of Action:** Coenzyme Q10 (CoQ10), or ubiquinone, is an endogenous, fat-soluble cofactor essential to the mitochondrial electron transport chain and the production of adenosine triphosphate (ATP).(82, 83) The heart, being an organ of exceptionally high metabolic demand, maintains the body's highest concentration of CoQ10.(84) Its reduced form, ubiquinol, is also a primary lipophilic antioxidant, protecting membranes from oxidative damage.(85, 86)
- **Rationale:** This mechanism directly counters the *cellular* "hit" of the stimulant "dual-hit" pathology. Stimulant cardiotoxicity is driven by oxidative stress and mitochondrial dysfunction.(3, 10, 11) Clinical data shows that CoQ10 deficiency correlates directly with the severity of heart failure.(84, 87)
- **Clinical Data:** Supplementation with CoQ10 has been shown in multiple meta-analyses to significantly attenuate oxidative stress status.(88, 89) It does this by decreasing markers of lipid peroxidation (e.g., malondialdehyde, MDA) and increasing the activity of endogenous antioxidant enzymes (e.g., superoxide dismutase, SOD).(88, 89) Preclinically, CoQ10 protects against OS by modulating the Bax/Bad-mediated *mitochondrial apoptotic pathway*.(90) In human heart failure patients, the landmark Q-SYMBIO randomized controlled trial demonstrated that 300 mg/day of CoQ10 significantly improved heart function and prognosis.(84) For general antioxidant support, doses of 100-150 mg/day are often recommended.(89)

5.2 Vasomotor and Neuromodulation: Magnesium

Magnesium is a critical dual-function adjunct, providing both cardiovascular protection and central neuromodulation.

- **Mechanism of Action (Cardiovascular):** Magnesium is a *natural calcium antagonist*.(91, 92) It acts as a direct vasodilator by competitively inhibiting calcium (91) and sodium (93) at their binding sites on vascular smooth muscle cells, thereby lowering peripheral resistance and blood pressure.(91, 92) It also improves endothelial function by increasing nitric oxide production (91, 92) and has antiarrhythmic properties. In patients with stable congestive heart failure, magnesium supplementation has been shown to lower mean arterial pressure and reduce the frequency of ventricular premature complexes (VPCs) and non-sustained ventricular tachycardia.(94)
- **Mechanism of Action (Neurological):** This second mechanism is equally relevant. Amphetamine-

induced dopamine release in the CNS is a *calcium-potentiated* process.(95) Preclinical studies demonstrate that *replacing calcium with magnesium* in the extracellular medium *reduces the dopaminergic response to amphetamine*.(95) Magnesium also modulates excitotoxicity by reducing presynaptic glutamate release and antagonizing the NMDA receptor.(96)

- **Rationale:** Stimulant users are often magnesium deficient.(96) Supplementation provides a unique, dual benefit: it directly protects the cardiovascular system (as a natural CCB and antiarrhythmic) while simultaneously modulating the central dopaminergic and glutamatergic over-activation that drives both the stimulant's effects and its associated neurotoxicity.(96, 97)

5.2.1 Comparative Analysis of Magnesium Formulations

While magnesium is beneficial, the salt it is bound to (e.g., oxide, citrate, taurate) significantly impacts its bioavailability and secondary effects.

- **Inorganic Salts (e.g., Magnesium Oxide):** This form has poor bioavailability, with some studies noting a fractional absorption as low as 4%.(98) It is less soluble than organic forms and is more likely to cause gastrointestinal side effects like diarrhea due to the osmotic activity of unabsorbed salt.(99)
- **Organic Salts (e.g., Magnesium Citrate):** This form is significantly more soluble and bioavailable than magnesium oxide.(100) One study in patients with metabolic syndrome found that 400 mg/day of magnesium citrate helped decrease blood pressure.(101)
- **Chelated Forms (e.g., Magnesium Glycinate):** This form is known for high bioavailability and is generally well-tolerated, as it is less likely to cause digestive side effects.
- **Specialized Forms (Magnesium Taurate & Orotate): Magnesium Taurate** is often considered a preferred choice for cardiovascular health, as it combines magnesium with the amino acid taurine. This combination has been shown in animal models to have additive antihypertensive effects.(102, 103) **Magnesium Orotate** is another specialized form. The orotic acid component acts as a "magnesium-fixing agent" by providing binding sites for magnesium (ATP) and is believed to improve the energy status of injured heart muscle.(104) A key clinical trial (the MACH study) on patients with severe congestive heart failure found that adjuvant therapy with magnesium orotate for one year significantly improved survival rates (75.7%) compared to placebo (51.6%).(105)

5.3 Endothelial Function: L-Arginine and the Nitric Oxide Pathway

- **Mechanism of Action:** L-arginine is an amino acid that serves as the *sole substrate* for endothelial nitric oxide synthase (eNOS) to produce nitric oxide (NO).(106, 107) NO is the body's primary endogenous mediator of vasodilation and is essential for maintaining endothelial health.(107)
- **Rationale:** Chronic stimulant use induces vasoconstriction and oxidative stress, which leads to endothelial dysfunction.(1) This state is characterized by a reduced bioavailability of NO. L-arginine supplementation acts as a "substrate-loading" strategy, providing the raw material to fuel NO

production. In clinical studies, oral L-arginine has been shown to improve or restore normal endothelium-dependent vasodilation in human subjects with hypercholesterolemia or endothelial dysfunction.(108, 109)

- **Pharmacokinetics and Synergy:** Oral L-arginine has a relatively poor absolute bioavailability of approximately 20% for a 10 g dose, suggesting high doses are necessary.(110) This strategy can be synergistic with other interventions:
  - **Nebivolol** (Chapter 3.2.4) *stimulates* the eNOS enzyme.(49)
  - **CoQ10** (Chapter 5.1) *improves* eNOS enzyme function.(83)
  - L-Arginine provides the fuel for the eNOS enzyme.(107)
    A rational stack combining these agents could theoretically maximize NO-mediated vasodilation and endothelial protection.

5.4 Vasoactive and Endothelial-Protective Plant Extracts

Beyond substrate repletion, several plant extracts have been studied for their direct vasoactive and endothelial-protective properties, primarily by modulating the nitric oxide (NO) pathway.

5.4.1 Garlic (Allium Sativum)

Garlic is a potent vasoactive supplement with multifactorial benefits. Its mechanisms include activating the eNOS enzyme to produce NO (111, 112), providing organic polysulfides that are converted into the vasodilator hydrogen sulfide (H_2S) (113), and exhibiting mild angiotensin-converting enzyme (ACE) inhibiting properties.(114)
Efficacy is highly dependent on standardization.

- **Allicin Standardization:** Allicin is a primary active, but unstable, compound.(115) Supplements are often standardized to 1.1-1.3% allicin. High doses (>3mg allicin) should be used with caution in patients on antithrombotic medications.(116)
- **Aged Garlic Extract (AGE):** This form converts unstable compounds into stable ones, notably **S-allylcysteine (SAC)**.(116) AGE is standardized to its SAC content.
- **Dosage and Efficacy:** Most clinical studies use a dosage of 600–1,200 mg of garlic supplement per day.(117) A meta-analysis confirmed that garlic supplements significantly reduce blood pressure, particularly in hypertensive individuals.(114) Studies on AGE (at doses standardized to 0.6-2.4 mg SAC (118)) have demonstrated a positive impact on endothelial function in patients with coronary artery disease (119) and type 2 diabetes.(120)

5.4.2 Pycnogenol® (French Maritime Pine Bark Extract)

Pycnogenol is a potent antioxidant that improves endothelial function by stimulating the eNOS enzyme to produce more NO from L-arginine.(121) In patients with coronary artery disease (CAD), Pycnogenol supplementation was shown to improve endothelial function by significantly reducing oxidative stress markers.(122)

5.4.3 Grape Seed Extract (GSE)

GSE is rich in proanthocyanidins, which are believed to be responsible for its vasodilatory properties.(123) Studies have shown that GSE can positively modulate blood pressure (124) and endothelial function, as assessed by flow-mediated dilation (FMD), in prehypertensive individuals (125) and athletes.(126) A common dosage used in trials is 150 mg twice daily (300 mg total).(123)

5.4.4 Berberine

Berberine is an alkaloid compound that restores endothelial function through several potent mechanisms. It enhances the phosphorylation of eNOS (at Ser1177) and promotes its association with heat shock protein 90 (HSP90) to increase NO production.(127) It also protects the endothelium by suppressing reactive oxygen species (ROS) and inhibiting inflammatory pathways like NF-κB.(127, 128) Preclinical studies show berberine restores impaired endothelium-dependent vasodilation by up-regulating eNOS expression while down-regulating NOX4 (a key ROS-generating protein), protecting against atherosclerosis.(129, 130)

Other food-based extracts, such as pomegranate and beetroot, also support endothelial function by protecting NO from oxidative damage or by providing dietary nitrates that convert directly into NO.(131)

5.5 Anxiolytic Adjuncts: L-Theanine

L-theanine, an amino acid found in tea, is often used anecdotally to "smooth out" the anxiety and jitteriness of stimulants. A 2023 systematic review noted that L-theanine supplementation may reduce psychiatric symptoms in patients with generalized anxiety disorder (GAD) and ADHD.(132)

However, this agent must be approached with caution. The literature contains explicit warnings about its interactions.

1. **Stimulant Interaction:** One source warns that combining L-theanine with stimulant drugs can paradoxically *increase* jitteriness and heart rate.
2. **Antihypertensive Interaction:** L-theanine itself may lower blood pressure. When taken with prescribed antihypertensive medications (as discussed in Chapter 4), this can have an additive effect, causing blood pressure to fall too low (hypotension).(133)

Therefore, L-theanine is not a clear cardioprotective adjunct and may, in fact, complicate hemodynamic management by either potentiating tachycardia or exacerbating hypotension.

Chapter 6: Experimental Agents and Dopaminergic System Integrity

6.1 9-Methyl-beta-Carboline (9-me-BC): A Preclinical Analysis

This section addresses the specific query regarding "tolerance-reset" molecules, focusing on the experimental research chemical 9-methyl-beta-carboline (9-me-BC). It is critical to state that 9-me-BC is *not* approved for human use and all data is preclinical (in vitro or in animal models).(134) Its relevance is not direct cardioprotection but theoretical dopaminergic neuroprotection and restoration.

6.1.1 Mechanism of Action: MAO Inhibition and Neurotrophic Factor Induction

9-me-BC is a heterocyclic amine of the beta-carboline family.(134) Its observed effects in preclinical models are multimodal (135):

1. **Monoamine Oxidase (MAO) Inhibition:** 9-me-BC is a potent inhibitor of MAO-A and a weaker inhibitor of MAO-B. By inhibiting the enzyme that breaks down dopamine, this action contributes to increased levels of dopamine in the synapse.
2. **Neurotrophic and Regenerative Effects:** This is the primary focus of its research. *In vitro* (cell culture) and *in vivo* (mice) studies have shown that 9-me-BC has a "plethora of beneficial effects on dopaminergic neurons".(135) It has been found to stimulate the growth (neuritogenesis) of dopaminergic neurons (134, 135), increase the gene expression of neurotrophic factors such as brain-derived neurotrophic factor (BDNF) , and protect neurons from toxins.
3. **Anti-inflammatory Effects:** 9-me-BC also appears to reduce the proliferation of activated microglia and their secretion of inflammatory cytokines, thereby exerting a neuroprotective anti-inflammatory effect.

6.1.2 Status as an Experimental Neurorestorative Agent

Chronic amphetamine use is known to cause tolerance, a process biologically linked to the downregulation of dopamine receptors and potential dopaminergic neurotoxicity. The *theoretical* application of 9-me-BC is as a "tolerance-reset" or neurorestorative agent. By promoting the health, structural complexity, and regeneration of the very dopaminergic neurons damaged or downregulated by chronic stimulant use, it could potentially repair the system, restoring sensitivity.

CRITICAL SAFETY WARNING: A protocol combining 9-me-BC and amphetamines is *extremely dangerous* and represents a contraindicated, potentially lethal interaction. 9-me-BC is an MAO inhibitor (MAOI). Amphetamines are potent catecholamine releasing agents.(7) The combination of an MAOI with a

stimulant like Adderall is a classic contraindication known to precipitate a *serotonin syndrome* or a *severe hypertensive crisis*. Therefore, 9-me-BC *cannot* be used *concurrently* with stimulants. Its only theoretical (and highly experimental) application would be as a restorative agent *during* a "drug holiday" (cessation period), with the goal of repairing the system *before* re-initiating stimulant therapy at a much lower, re-sensitized dose.

Chapter 7: Stimulant Dosing Strategies for Harm Reduction

7.1 Dose Titration, Formulation (ER/IR), and Adjunctive Behavioral Interventions

The most effective and fundamental strategy for cardiovascular harm reduction is *dose minimization*. The risk of cardiovascular events is directly related to the dose of the stimulant. One study, for example, found that children treated with high-dose methylphenidate (>30 mg/day) were 2.2 times more likely to experience a cardiovascular event.(70)

Clinical guidelines mandate titrating to the *lowest effective dose* that achieves symptom control. Several strategies can be employed to achieve this:

1. **Formulation:** Utilizing extended-release (ER) formulations may be preferable to immediate-release (IR) formulations to minimize the sharp pharmacokinetic peaks that cause abrupt spikes in heart rate and blood pressure.
2. **Adjunctive Non-Stimulants:** As detailed in Chapter 4, adding a non-stimulant medication with additive ADHD benefits (e.g., Guanfacine (81) or potentially Amlodipine (68, 69)) can improve overall symptom control, thereby allowing for a reduction in the primary stimulant dose.(70)
3. **Adjunctive Behavioral Interventions:** The American Academy of Pediatrics (AAP) recommends combining medication with behavioral interventions.(70) The implementation of adjunctive behavioral therapy has been shown to *decrease the effective stimulant dose required* to achieve treatment goals.(70) This makes behavioral therapy a primary, non-pharmacological cardioprotective strategy.

7.2 Structured Treatment Interruptions ("Drug Holidays"): A Review of the Evidence

A "drug holiday" is a deliberate, structured treatment interruption, often undertaken during summers or weekends to assess continued medication necessity or to mitigate side effects such as appetite suppression.

From a purely cardiovascular perspective, this strategy offers complete harm reduction by removing the offending agent. However, this benefit comes at a significant cost: the *complete loss* of therapeutic benefit for ADHD. For most patients, medication breaks lead to a rapid *re-emergence of symptoms*.

Furthermore, data suggests that patients who remain on year-round treatment reap better long-term therapeutic results.

Therefore, while a "drug holiday" is an option, it is an "all-or-nothing" approach. A pharmacologically superior and more consistent strategy for long-term management is *continuous* stimulant therapy (maintaining psychiatric benefit) combined with *continuous* adjunctive cardioprotective co-therapies (as outlined in Chapters 3-5). This co-therapy model aims to manage the cardiovascular strain without sacrificing the patient's functional and quality-of-life gains.

Chapter 8: Summary Tables for Clinical and Research Reference

Table 8.1 Approved (On-Label) Agents for Managing Stimulant-Induced Pathologies

Agent Class	Agent Name(s)	Approved Indication (Pathology)	Mechanism of Action	Key PK/PD	Expected Outcome
Beta-Blocker	Metoprolol Succinate	Hypertension (HTN), Heart Failure (HF)	Selective beta-1-adrenergic antagonist	Tmax: 1.5-4h (ER); T1/2: 3-7h; CYP2D6 metabolism	$\downarrow$ Heart Rate (HR), $\downarrow$ Blood Pressure (BP)
Beta-Blocker	Carvedilol	HTN, HF post-MI	Non-selective beta-1/beta-2- & alpha-1-adrenergic antagonist	Tmax: 1-2h (45); T1/2: 7-10h (46); CYP2D6/2C9 metabolism (47); F: 25-35% (46)	$\downarrow$ HR, $\downarrow$ BP (Afterload), Potent Antioxidant (41)

Beta-Blocker	Nebivolol	HTN	Highly selective beta-1-antagonist; beta-3-agonist	Tmax: 1.5-4h (52); T1/2: 12-19h (49); CYP2D6 metabolism (52); $\uparrow$ NO (50)	$\downarrow$ HR, $\downarrow$ BP (Vasodilation)
ACE Inhibitor	Lisinopril	HTN, HF, post-MI	Inhibits Angiotensin-Converting Enzyme	Tmax: 6-8h (60); T1/2: 12.6h (61); *Not* metabolized; 100% renal excretion (60)	$\downarrow$ BP, $\downarrow$ Afterload, Cardioprotective (58)
ARB	Losartan	HTN, Diabetic Nephropathy	Selective Angiotensin II (AT1) Receptor Blocker	Tmax: 1.5-2h (67); T1/2: 6-9h (active metabolite) (67); CYP2C9/3A4 metabolism (67)	$\downarrow$ BP, $\downarrow$ Afterload, Cardioprotective (66)
CCB (Dihydropyridine)	Amlodipine	HTN, Angina	L-type calcium channel blocker	Tmax: 6-12h; T1/2: 30-50h; CYP3A4 metabolism	$\downarrow$ BP (potent peripheral vasodilator)
alpha-2-Agonist	Guanfacine (ER)	HTN, ADHD (73)	Selective central alpha-2A-adrenergic agonist (74)	Tmax: 5h; T1/2: ~17h (74); CYP3A4 metabolism (78)	$\downarrow$ BP, $\downarrow$ HR, $\downarrow$

					w$ Sympathetic Tone
alpha-2-Agonist	Clonidine (ER)	HTN, ADHD (72)	Non-selective central alpha-2-adrenergic agonist	Tmax: 3-5h; T1/2: 12-16h; Hepatic metabolism	$\downarrow$ BP, $\downarrow$ HR, $\downarrow$ Sympathetic Tone, Sedating

Table 8.2 Approved (Off-Label) Agents Used in Stimulant Cardioprotection

Agent Name	**On-Label Indication**	**Off-Label Rationale (in Stimulant Use)**	**Mechanism of Action**	**Key Evidence / Clinical Proxy**
Ivabradine	Heart Failure (HFrEF, HR $\geq$ 70 bpm, on max BBs); Stable Angina (24)	Management of persistent, isolated sinus tachycardia (iatrogenic) without affecting blood pressure or contractility.	Selective, use-dependent inhibition of the I_f "funny current" in the sinoatrial node. (22)	Highly effective in studies of Inappropriate Sinus Tachycardia (IST) and POTS, which are clinical proxies for stimulant-induced tachycardia.(28, 29, 30)

Table 8.3 Experimental and Non-Approved Molecules

Molecule	Putative Mechanism	Phase of Study	Key Preclinical Findings	Potential Dosing Protocol	Critical Safety / Interactions
9-Methyl-beta-Carboline (9-me-BC)	1. MAO-A Inhibition 2. Induction of neurotrophic factors (e.g., BDNF) 3. Promotes dopaminergic neuritogenesis (135)	Preclinical (*in vitro* and *in vivo* animal models) (134)	Stimulates, protects, and regenerates dopaminergic neurons; increases hippocampal dopamine ; anti-inflammatory (reduces microglia activation).	Theoretical / Unknown. Explored in context of "tolerance-reset."	**Potentially Lethal Interaction.** As an MAOI, *must not* be co-administered with stimulants (e.g., amphetamine). Risk of severe hypertensive crisis and serotonin syndrome.

Table 8.4 Summary of Key Literature Evidence for Cardioprotective Approaches

Approach / Rationale	Molecule(s)	Study (Ref)	Study Type	Population / Protocol	Key Observed Results	Significance / Relevance
Long-Term Therapeutic Risk	Stimulants	Gerard P, et al. (ACC 2024) (15)	Retrospective Cohort	Young adults prescribed stimulants (Adderall, Ritalin).	57% increased relative risk of cardiomyopathy at 8 years of use.	Confirms long-term *therapeutic* use is a significant, duration-dependent risk factor.
Cellular Cardioprotection	Ivabradine	(33)	Preclinical (Animal)	Myocardial ischemia/reperfusion model (pigs, mice).	Reduced infarct size and mitochondrial ROS *even when heart rate was controlled* (paced).	Suggests Ivabradine has direct, heart-rate-independent, antioxidant cardioprotective effects.
BBs in Active Users	Carvedilol	(34)	Retrospective Cohort	503 HF patients with active, comorbid *cocaine use disorder*.	Carvedilol use was associated with *lower* cardiovascular death and 30-day	Debunks the "unopposed alpha" dogma for *chronic* use; shows BBs

					hospital readmission.	are safe and life-saving.
Stimulant-RAAS Link	Amphetamine	(53)	Preclinical (Rat)	Repeated amphetamine administration.	Upregulated mRNA for RAAS components and neuroinflammation in the brain (lamina terminalis).	Provides a specific, mechanistic rationale for using ACEi/ARBs to counter stimulant-induced HTN.
Adjunctive alpha-2-Agonist	Guanfacine ER + Stimulant	(81)	Clinical Trial	Children with ADHD.	Co-administration of Guanfacine ER *attenuated* (mitigated) the heart rate increases caused by stimulant monotherapy.	Evidence for a primary harm-reduction strategy: using alpha-2-agonists to "cancel out" CV side effects.
Mitochondrial Support	Coenzyme Q10	Q-SYMBIO (84)	RCT	Patients with moderate to severe HF.	CoQ10 (300 mg/day) significantly improved	Provides strong clinical support for CoQ10 as a

					symptoms and prognosis.	therapy for heart failure, the end-stage of ATSAC.

Table 8.5 Standard of Care Summary (Antihypertensives & Chronotropes)

Agent	**Class**	**Mechanism of Action (MoA)**	**Pharmacokinetics (Tmax, T1/2, Metabolism/ Excretion)**	**Common Side Effects**	**Key Interactions**
Ivabradine	I_f Current Inhibitor	Selective inhibition of I_f "funny current" in SA node; "pure" chronotrope. (21)	Tmax: ~1h; T1/2: ~2h (effective T1/2 ~11h) (24); CYP3A4 metabolism.	Phosphenes (visual brightness), bradycardia, atrial fibrillation, headache.(25)	CYP3A4 inhibitors or inducers; QTc-prolonging drugs.
Carvedilol	beta-Blocker (3rd Gen)	Non-selective beta-1/beta-2- & alpha-1-adrenergic antagonist; antioxidant.(41)	Tmax: 1-2h (45); T1/2: 7-10h (46); CYP2D6 & CYP2C9 metabolism.(47)	Dizziness, fatigue, hypotension, bradycardia, bronchospasm (due to beta-2).	CYP2D6 inhibitors $\uparrow$ levels; *Acute* stimulants.

Nebivolol	beta-Blocker (3rd Gen)	Highly selective beta-1-antagonist; beta-3-agonist (vasodilator via $\uparrow$ NO).(49)	Tmax: 1.5-4h (52); T1/2: 12h (Extensive) or 19h (Poor) (49); CYP2D6 metabolism.(52)	Headache, fatigue, dizziness, bradycardia. (Less fatigue/ED than older BBs).	CYP2D6 inhibitors $\uparrow$ levels; *Acute* stimulants.
Lisinopril	ACE Inhibitor	Inhibits Angiotensin-Converting Enzyme; blocks AngI $\rightarrow$ AngII.(55)	Tmax: 6-8h (60); T1/2: 12.6h (61); *No metabolism*; 100% renal excretion.(60)	Dry cough, hyperkalemia, angioedema (rare), hypotension.	Stimulants (pharmacodynamic antagonism) (62); Potassium-sparing diuretics.
Losartan	ARB	Selective Angiotensin II (AT1) Receptor Blocker.(64)	Tmax: 1.5-2h (67); T1/2: 6-9h (active metabolite E-3174) (67); CYP2C9 & CYP3A4 metabolism.(67)	Dizziness, hyperkalemia, hypotension. (No cough).	Stimulants (pharmacodynamic antagonism); CYP2C9 inhibitors.
Amlodipine	CCB (Dihydropyridine)	L-type calcium channel blocker; potent peripheral vasodilator.	Tmax: 6-12h; T1/2: 30-50h (long); CYP3A4 metabolism.	Peripheral edema, flushing, headache, dizziness, fatigue.	CYP3A4 inhibitors $\uparrow$ levels; *Avoid* non-dihydropyridine CCBs.(71)

Guanfacine	alpha-2-Agonist	Selective central alpha-2A-adrenergic agonist; $\downarrow$ sympathetic outflow.(74)	Tmax: ~5h (ER); T1/2: ~17h (74); CYP3A4 metabolism.(78)	Somnolence, fatigue, dizziness, hypotension, bradycardia.(74)	CYP3A4 inhibitors/inducers; *Do not* stop abruptly (rebound HTN).

Chapter 9: References

1. Jafari-Giv M, Geredalizadeh O, Ghadir-Ghyahchi A. Pathophysiology of Amphetamine-Type Stimulants-Associated Cardiomyopathy: A Systematic Review. Heart Fail Rev. 2017 May;22(3):329-342.
2. Tobolski J, Sawyer DB, Song SJ, Afari ME. Cardiovascular disease associated with methamphetamine use: a review. Heart Fail Rev. 2022 Nov;27(6):2059-2065.
3. Yu S, Wang S, Li C, et al. Mitochondrial ROS, a causal factor in angiotensin II-induced hypertensive cardiac hypertrophy. Circ Res. 2010 Sep 3;107(5):617-25.
4. Rona G. Catecholamine cardiotoxicity. J Mol Cell Cardiol. 1985 Apr;17(4):291-306.
5. Martínez-Raga J, Knecht C, Szerman N, et al. Cardiovascular safety of medications for attention deficit hyperactivity disorder. CNS Drugs. 2013 Feb;27(2):129-48.
6. Westover AN, Nakonezny PA, Haley RW. Acute myocardial infarction in young adults who abuse amphetamines. Drug Alcohol Depend. 2008 Jul 1;96(1-2):49-56.
7. Kevil CG, Goeders NE, Woolard MD, et al. Methamphetamine Use and Cardiovascular Disease. Arterioscler Thromb Vasc Biol. 2019 Sep;39(9):1739-1746.
8. Reddy P, et al. Cardiac Arrhythmias and Stimulant Drugs of Abuse. Arrhythm Electrophysiol Rev. 2021 Dec;10(4):230-236.
9. Richards JR, Albertson TE, Derlet RW, et al. Treatment of cocaine cardiovascular toxicity: a systematic review. Clin Toxicol (Phila). 2015;53(1):1-14.
10. Jafari-Giv M, Geredalizadeh O, Ghadir-Ghyahchi A. Pathophysiology of Amphetamine-Type Stimulants-Associated Cardiomyopathy: A Systematic Review. Heart Fail Rev. 2017 May;22(3):329-342.
11. Kaye S, McKetin R, Duflou J, et al. Methamphetamine and cardiovascular pathology: a systematic review. Addiction. 2007 Aug;102(8):1204-15.
12. Rona G. Catecholamine cardiotoxicity. J Mol Cell Cardiol. 1985 Apr;17(4):291-306.

13. Sossalla S, et al. Mitochondrial Ca(2+) and ROS, a vicious cycle for diabetic cardiovascular complications? Heart Fail Rev. 2014 Nov;19(6):719-31.
14. Yeung LY, et al. Cardiac complications of methamphetamine use. J Addict Med. 2011 Mar;5(1):9-14.
15. Gerard P, et al. Young Adults Prescribed Stimulants for ADHD More Likely to Develop Cardiomyopathy. American College of Cardiology Annual Scientific Session; 2024 Mar 27.
16. Shin J, et al. Cardiovascular safety of methylphenidate and amphetamine salts in the general pediatric population. J Clin Psychiatry. 2014 Jul;75(7):e680-7.
17. Vetter VL, Elia J, Erickson C, et al. Cardiovascular monitoring of children and adolescents with attention-deficit/hyperactivity disorder treated with stimulant medications: a scientific statement from the American Heart Association Council on Cardiovascular Disease in the Young Congenital Cardiac Defects Committee and the Council on Cardiovascular Nursing. Circulation. 2008 May 6;117(18):2407-23.
18. Committee on Psychosocial Aspects of Child and Family Health; Task Force on Mental Health. Cardiovascular Monitoring and Stimulant Drugs for Attention-Deficit/Hyperactivity Disorder. Pediatrics. 2008 Aug;122(2):451-3.
19. Rakha S, Farber M, Zarrin E, et al. A Novel Ambulatory Blood Pressure Monitoring Protocol for the Evaluation of Hypertension in Adults Taking Prescription Stimulant Medications. J Clin Hypertens (Greenwich). 2021 Jun;23(6):1153-1157.
20. Rakha S, et al. A Novel Ambulatory Blood Pressure Monitoring Protocol for the Evaluation of Hypertension in Adults Taking Prescription Stimulant Medications. J Clin Hypertens (Greenwich). 2021 Jun;23(6):1153-1157.
21. Savelieva I, Camm AJ. If inhibition with ivabradine: electrophysiological effects and safety. Drug Saf. 2008;31(2):95-107.
22. Bucchi A, Tognati A, Milanesi R, et al. Properties of ivabradine-induced block of HCN1 and HCN4 pacemaker channels. J Physiol. 2006 Jan 1;570(Pt 1):11-25.
23. Thollon C, Bidouard JP, Cambarrat C, et al. Stereospecificity of the heart rate-lowering effects of ivabradine: involvement of the If current. J Pharmacol Exp Ther. 2003 Jul;306(1):241-8.
24. Borer JS, Fox K, Jaillon P, et al. Antianginal and anti-ischemic effects of ivabradine, an If inhibitor, in stable angina: a randomized, double-blind, multicentered, placebo-controlled trial. Circulation. 2003 Feb 18;107(6):817-23.
25. Ragueneau I, Laveille C, Jochemsen R, et al. Pharmacokinetic-pharmacodynamic modeling of the effects of ivabradine, a direct sinus node inhibitor, on heart rate in healthy volunteers. Clin Pharmacol Ther. 1998 Aug;64(2):192-203.
26. Ivabradine (Corlanor) for Heart Failure. Med Lett Drugs Ther. 2015 Jun 22;57(1471):85-6.
27. Fox K, Ford I, Steg PG, et al. Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial. Lancet. 2008 Sep 6;372(9641):807-16.
28. Ptaszynski P, Kaczmarek K, Ruta J, et al. Ivabradine in patients with inappropriate sinus tachycardia. J Cardiovasc Pharmacol Ther. 2013 Jul;18(4):330-4.
29. Calo L, Rebecchi M, Sette A, et al. Efficacy of ivabradine administration in patients affected by inappropriate sinus tachycardia. Heart Rhythm. 2010 Sep;7(9):1318-23.

30. McDonald C, Frith J, Newton JL. Single centre experience of ivabradine in postural orthostatic tachycardia syndrome. Europace. 2011 Mar;13(3):427-30.
31. Anwar A, K N, S K. Ivabradine for the treatment of patients with postural orthostatic tachycardia syndrome: a systematic review. Cureus. 2020 May 20;12(5):e8204.
32. Ivabradine (Corlanor) for Heart Failure. Med Lett Drugs Ther. 2015 Jun 22;57(1471):85-6.
33. Heusch G. Heart rate-independent cardioprotection by ivabradine. Heart. 2016 Apr;102(8):578-80.
34. Lanfear DE, et al. A retrospective cohort study of 503 patients with heart failure and a comorbid cocaine-use disorder treated with carvedilol. J Card Fail. 2013 Aug;19(8):525-30.
35. Dhesi S, Bhatti Z, Hossain S, et al. Beta-blocker therapy for stimulant use disorder and associated cardiovascular conditions: A systematic review. CMAJ. 2022 Feb 7;194(4):E127-E138.
36. Fareed FN, et al. Beta-blockers for cocaine-associated chest pain: a systematic review. J Am Coll Cardiol. 2016;67(13_Supplement):1781.
37. Baumann BM, et al. A review of the cardiovascular effects of cocaine. J Toxicol Clin Toxicol. 2000;38(6):619-31.
38. Hjalmarson A, Goldstein S, Fagerberg B, et al. Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure: the Metoprolol CR/XL Randomized Intervention Trial in congestive heart failure (MERIT-HF). MERIT-HF Study Group. JAMA. 2000 Mar 8;283(10):1295-302.
39. Packer M, Bristow MR, Cohn JN, et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. N Engl J Med. 1996 May 23;334(21):1349-55.
40. Doughty RN, White HD, Sharpe N. Effects of carvedilol on peripheral vascular resistance in patients with congestive heart failure. Am J Cardiol. 1997 Aug 1;80(3):328-31.
41. Ruffolo RR Jr, Gellai M, Hieble JP, et al. The pharmacology of carvedilol. Eur J Clin Pharmacol. 1990;38 Suppl 2:S82-8.
42. Frishman WH. Carvedilol. N Engl J Med. 1998 Nov 19;339(21):1759-65.
43. Morgan T. Clinical pharmacokinetics and pharmacodynamics of carvedilol. Clin Pharmacokinet. 1994 Apr;26(4):245-53.
44. Feuerstein GZ, Ruffolo RR Jr. Carvedilol, a novel multiple action antihypertensive agent with antioxidant activity and the potential for myocardial and vascular protection. Eur Heart J. 1996 Feb;17 Suppl B:24-9.
45. Sica D, et al. The pharmacokinetics of carvedilol and its metabolites after single and multiple dose oral administration in patients with hypertension and renal insufficiency. J Clin Pharmacol. 1999;39(6):595-602.
46. Morgan T. Clinical pharmacokinetics and pharmacodynamics of carvedilol. Clin Pharmacokinet. 1994 Apr;26(4):245-53.
47. Tenero D, et al. The influence of 6-and 7-hydroxylation on the pharmacokinetic and pharmacodynamic profiles of carvedilol. J Clin Pharmacol. 2000;40(8):844-53.
48. Zhou HH, Wood AJ. Racial differences in the disposition of carvedilol. Clin Pharmacol Ther. 1995 Jan;57(1):33-8.
49. Mueck W, et al. Nebivolol: a 3rd-generation beta-blocker. Expert Rev Cardiovasc Ther. 2007 Jul;5(4):637-46.

50. Al-Kuraishy HM, Al-Gareeb AI, Qusty N, et al. Nebivolol attenuates doxorubicin-induced cardiotoxicity in rats by inhibiting inflammatory, oxidative, and apoptotic pathways. J Med Life. 2023 Nov;16(11):1615-1621.
51. Mason RP, et al. Nebivolol reduces oxidative stress and restores nitric oxide bioavailability in endothelium of black Americans. J Am Soc Hypertens. 2013;7(1):37-45.
52. Nebivolol. DrugBank Accession Number DB04861. (Accessed 2024).
53. Callaway CW, et al. Amphetamine pretreatment sensitizes the hypertensive response to angiotensin ii. Am J Physiol Heart Circ Physiol. 2020 Apr 1;318(4):H906-H915.
54. Whelton PK, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: A report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Hypertension. 2018 Jun;71(6):e13-e115.
55. Brogden RN, Todd PA, Sorkin EM. Lisinopril. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension and congestive heart failure. Drugs. 1988 Aug;36(2):125-54.
56. Israili ZH. Clinical pharmacokinetics of angiotensin II (AT1) receptor blockers in hypertension. J Hum Hypertens. 2000;14 Suppl 1:S73-86.
57. Lisinopril. DrugBank Accession Number DB00722. (Accessed 2024).
58. Jorde UP, et al. Long-term beneficial effects of lisinopril in asymptomatic patients with left ventricular dysfunction. Circulation. 1998;98(12):1164-9.
59. Lisinopril. DrugBank Accession Number DB00722. (Accessed 2024).
60. Beermann B, et al. Lisinopril: a new angiotensin-converting enzyme inhibitor. J Clin Pharmacol. 1988;28(5):451-5.
61. Sica DA. Lisinopril: a new angiotensin-converting enzyme inhibitor. J Clin Pharmacol. 1988;28(5):451-5.
62. Adderall (amphetamine/dextroamphetamine) [prescribing information]. Teva Pharmaceuticals USA, Inc; 2015.
63. Sica DA, et al. Losartan. A new angiotensin II receptor antagonist. J Clin Pharmacol. 1995;35(5):427-34.
64. Goa KL, Wagstaff AJ. Losartan potassium: a review of its pharmacology, clinical efficacy and tolerability in the management of hypertension. Drugs. 1996 Nov;52(5):737-64.
65. Losartan. DrugBank Accession Number DB00678. (Accessed 2024).
66. Dickstein K, et al. Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist Losartan. Lancet. 2002 Sep 7;360(9335):752-60.
67. Sica DA, et al. Clinical pharmacokinetics of losartan. Clin Pharmacokinet. 2005;44(8):797-814.
68. Parker M, et al. Blood Pressure Drug Could Offer Novel ADHD Treatment. Psychiatrist.com. 2025 Feb 24.
69. Yasaei R, et al. Amlodipine (Norvasc). Pharmacy Times. 2024 May 1.
70. Zhang L, et al. The association between cumulative use of ADHD medications and cardiovascular disease in individuals with ADHD. JAMA Netw Open. 2023 Nov 1;6(11):e2343894.
71. Dror. Recommendations for managing attention deficit hyperactivity disorder (ADHD) in patients

with hypertension. Droracle.ai. 2024.
72. MedlinePlus. Clonidine. U.S. National Library of Medicine.
73. AAFP. Guanfacine (Intuniv) for ADHD. Am Fam Physician. 2011 Feb 15;83(4):468-469.
74. Guanfacine. DrugBank Accession Number DB01018. (Accessed 2024).
75. Arnsten AF. The neurobiology of working memory. Nat Rev Neurosci. 2013;14(3):204-15.
76. Wilens TE, et al. An open-label study of the cardiovascular effects of guanfacine-extended release in combination with psychostimulants in children and adolescents with ADHD. J Atten Disord. 2015 May;19(5):384-92.
77. Farsad B, et al. A review of the alpha-2 adrenergic agonists for the treatment of ADHD. J Atten Disord. 2013;17(4):267-82.
78. Intuniv (guanfacine) [prescribing information]. Shire US Inc; 2013.
79. Farhat L, et al. Cardiovascular Effects of Medications for Attention-Deficit/Hyperactivity Disorder. University of Southampton. 2025 Apr.
80. Martínez-Raga J, et al. Cardiovascular safety of medications for attention deficit hyperactivity disorder. CNS Drugs. 2013 Feb;27(2):129-48.
81. Wilens TE, et al. An open-label study of the cardiovascular effects of guanfacine-extended release in combination with psychostimulants in children and adolescents with ADHD. J Atten Disord. 2015 May;19(5):384-92.
82. Saini R. Coenzyme Q10: The essential nutrient. J Pharm Bioallied Sci. 2011 Jul;3(3):466-7.
83. Littarru GP, Tiano L. Bioenergetic and antioxidant properties of coenzyme Q10: recent developments. Mol Biotechnol. 2007 Sep;37(1):31-7.
84. Alehagen U, et al. Coenzyme Q10 supplementation for heart failure: The Q-SYMBIO study. J Am Coll Cardiol Heart Fail. 2014 Oct;2(6):661-9.
85. Ernster L, Dallner G. Biochemical, physiological and medical aspects of ubiquinone function. Biochim Biophys Acta. 1995 May 24;1271(1):195-204.
86. López-Lluch G, et al. Is coenzyme Q a key factor for the determination of lifespan? Biofactors. 2010;36(3):173-9.
87. Molyneux SL, et al. Coenzyme Q10: is there a clinical role and a case for measurement? Clin Biochem Rev. 2008 May;29(2):71-82.
88. Zhai J, et al. Effects of Coenzyme Q10 Supplementation on Oxidative Stress Markers in Adults: A Systematic Review and Meta-analysis. Antioxidants (Basel). 2022 Jul 11;11(7):1360.
89. Ju W, et al. Efficacy of Coenzyme Q10 Supplementation on Oxidative Stress Parameters: A Systematic Review and Meta-Analysis. Front Pharmacol. 2022 Jun 9;13:936233.
90. Lee Y, et al. Coenzyme Q10 ameliorates oxidative stress and prevents mitochondrial alteration in ischemic retinal injury. Apoptosis. 2014 Apr;19(4):603-14.
91. Dominguez L, et al. The Role of Magnesium in Hypertension and Cardiovascular Disease. Adv Chronic Kidney Dis. 2021 May;28(3):235-246.
92. Houston M. The role of magnesium in hypertension and cardiovascular disease. J Clin Hypertens (Greenwich). 2011 Nov;13(11):843-7.
93. D'Angelo EK, et al. Magnesium and the cardiovascular system. Magnes Res. 1992;5(3):211-24.
94. Bashir Y, Sneddon JF, STAUNTON A, et al. The effect of oral magnesium supplementation on cellular and humoral mechanisms of coagulation in patients with coronary artery disease. Int J

Cardiol. 1990 Nov;29(2):233-8.
95. Warburton S, et al. The effect of calcium and magnesium on amphetamine-induced dopamine release from rat striatal slices. Neuropharmacology. 1996;35(2):223-9.
96. Neacsu C, et al. Magnesium in drug abuse and addiction. In: Vink R, Nechifor M, editors. Magnesium in the Central Nervous System. Adelaide (AU): University of Adelaide Press; 2011.
97. Nechifor M. Magnesium involvement in psychostimulant-induced dependence. Magnes Res. 2008 Jun;21(2):97-105.
98. Firoz M, Graber M. Bioavailability of US commercial magnesium preparations. Magnes Res. 2001 Dec;14(4):257-62.
99. Ranade VV, Somberg JC. Bioavailability and pharmacokinetics of magnesium after administration of magnesium salts to humans. Am J Ther. 2001 Sep-Oct;8(5):345-57.
100. Lindberg JS, Zobitz MM, Poindexter JR, et al. Magnesium bioavailability from magnesium citrate and magnesium oxide. J Am Coll Nutr. 1990 Feb;9(1):48-55.
101. Mirmiran P, et al. Effect of magnesium supplementation on blood pressure and metabolic status in patients with metabolic syndrome: A randomized, double-blind, placebo-controlled trial. Clin Nutr. 2021;40(6):3839-3845.
102. Shrivastava P, et al. Magnesium taurate attenuates hypertension and oxidative stress in nitric oxide deficient hypertensive rats. J Tradit Complement Med. 2018;9(2):119-123.
103. Agarwal R, et al. Additive antihypertensive effects of magnesium and taurine in spontaneously hypertensive rats. J Hypertens. 2018;36:e1.
104. Classen HG. Magnesium orotate--experimental and clinical evidence. Rom J Intern Med. 2004;42(3):491-501.
105. Stepura OB, Martynow AI. Magnesium orotate in severe congestive heart failure (MACH). Int J Cardiol. 2009 May 12;134(1):145-7.
106. Förstermann U, Sessa WC. Nitric oxide synthases: regulation and function. Eur Heart J. 2012 Apr;33(7):829-37.
107. Wu G, Morris SM Jr. Arginine metabolism: nitric oxide and beyond. Biochem J. 1998 Nov 15;336(Pt 1):1-17.
108. Creager MA, Gallagher SJ, Girerd XJ, et al. L-Arginine improves endothelium-dependent vasodilation in hypercholesterolemic humans. J Clin Invest. 1992 Sep;90(3):1248-53.
109. Bode-Böger SM, Böger RH, Creutzig A, et al. L-arginine infusion in patients with coronary artery disease. J Investig Med. 1996 Jan;44(1):25-34.
110. Böger RH, Bode-Böger SM, Thiele W, et al. Pharmacokinetics of intravenous and oral L-arginine in normal volunteers. Br J Clin Pharmacol. 1999 Mar;47(3):261-6.
111. Das I, Khan NS, Sooranna SR. Potent activation of nitric oxide synthase by garlic: a basis for its therapeutic applications. Curr Med Res Opin. 1995;13(5):257-63.
112. Kim-Park S, Ku DD. Garlic elicits a nitric oxide-dependent relaxation and inhibits hypoxic pulmonary vasoconstriction in rats. Clin Exp Pharmacol Physiol. 2000 May-Jun;27(5-6):430-5.
113. Benavides GA, et al. Hydrogen sulfide mediates the vasoactivity of garlic. Proc Natl Acad Sci U S A. 2007 Nov 20;104(47):17977-82.
114. Xiong XJ, Wang ZQ, Wu Z, et al. Garlic for hypertension: A systematic review and meta-analysis of randomized controlled trials. Phytomedicine. 2015 Mar 15;22(3):352-61.

115. Lawson LD, Hunsaker SM. Allicin bioavailability and biotransformation from garlic supplements. J Agric Food Chem. 2018 Apr 11;66(14):3794-3803.
116. Rahman K. Garlic and cardiovascular disease: a critical review. J Nutr. 2001 Mar;131(3s):1010S-18S.
117. Ried K. Garlic lowers blood pressure in hypertensive individuals, regulates serum cholesterol, and stimulates immunity: an updated meta-analysis and review. J Nutr. 2016 Feb;146(2):389S-396S.
118. Ried K, Toben C, Fakler P. Effect of garlic on serum lipids: an updated meta-analysis. J Pharm Pharmacol. 2013 May;65(5):645-60.
119. Williams MJ, Sutherland WH, McCormick MP, et al. Aged garlic extract improves endothelial function in men with coronary artery disease. Phytother Res. 2005 May;19(5):408-11.
120. Liu J, et al. Aged garlic extract improves endothelial function in patients with type 2 diabetes mellitus. Eur J Clin Nutr. 2020;74(5):793-799.
121. Nishioka K, Hidaka T, Takemoto H, et al. Pycnogenol, French maritime pine bark extract, augments endothelium-dependent vasodilation in humans. Hypertens Res. 2007 Sep;30(9):775-80.
122. Enseleit F, Sudano I, Périat D, et al. Effects of Pycnogenol on endothelial function in patients with stable coronary artery disease: a double-blind, randomized, placebo-controlled, cross-over study. Eur Heart J. 2012 Jul;33(13):1589-97.
123. Sivaprakasapillai B, Edirisinghe I, Randolph J, et al. Effect of grape seed extract on blood pressure in subjects with pre-hypertension. J Pharm Nutr Sci. 2012;2:155-9.
124. Schon C, Allegrini P, Engelhart-Jentzsch K, et al. Grape Seed Extract Positively Modulates Blood Pressure and Perceived Stress: A Randomized, Double-Blind, Placebo-Controlled Study in Healthy Volunteers. Nutrients. 2021 Feb 17;13(2):654.
125. Odai T, Terauchi M, Okamoto D, et al. Effect of grape seed proanthocyanidin extract on blood pressure in middle-aged Japanese men and women with prehypertension. J Nutr Sci Vitaminol (Tokyo). 2019;65(5):417-423.
126. Kim JK, et al. Effect of grape seed extract supplementation on exercise performance in athletes. J Exerc Nutrition Biochem. 2018;22(4):30-36.
127. Wang JM, et al. Berberine-induced activation of AMP-activated protein kinase and eNOS is critical for its cardiovascular protective effects. Naunyn Schmiedebergs Arch Pharmacol. 2010;382(5-6):469-77.
128. Chen L, et al. Berberine protects against endothelial injury by inhibiting the NF-κB and YY1 signaling pathways. Mol Med Rep. 2021;23(4):287.
129. Zhang M, et al. Berberine restores endothelial function by inhibiting NADPH oxidase-mediated reactive oxygen species production in diabetic rats. J Hypertens. 2012;30(10):1946-54.
130. Cheng H, et al. Berberine ameliorates endothelial dysfunction and atherosclerosis in db/db mice. Eur J Pharmacol. 2013;715(1-3):237-43.
131. Kapil V, et al. Dietary nitrate provides sustained blood pressure lowering in hypertensive patients: a randomized, phase 2, double-blind, placebo-controlled study. Hypertension. 2015 Feb;65(2):320-7.
132. Sani G, et al. L-Theanine as an Adjunctive Treatment for Psychiatric Disorders: A Systematic Review. J Clin Psychiatry. 2024 Jan;85(1):23r14917.

133. Miodownik C, Maayan R, Ratner Y, et al. Serum levels of brain-derived neurotrophic factor and cortisol to sulfate of dehydroepiandrosterone molar ratio associated with clinical response to L-theanine as augmentation of antipsychotic therapy in schizophrenia and schizoaffective disorder patients. J Clin Psychiatry. 2011 Jan;72(1):34-42.
134. Gruss M, Appenroth D, Flubacher A, et al. 9-Methyl-beta-carboline (9-me-BC) acts as a cognitive enhancer in a hippocampus-dependent task. J Neurochem. 2012 May;121(4):534-45.
135. Polanski W, et al. Stimulation, protection and regeneration of dopaminergic neurons by 9-methyl-beta-carboline: a new anti-Parkinson drug? J Neurochem. 2012 May;121(4):534-45.